Gastroenterology

Lutathera (lutetium Lu 177 dotatate); Advanced Accelerator Applications; For the treatment of gastroenteropancreatic neuroendocrine tumors, Approved January 2018

Infections and Infectious Diseases

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection in adults, Approved February 2018

Oncology

Erleada (apalutamide); Janssen Oncology; For the treatment of prostate cancer, Approved February 2018 Lutathera (lutetium Lu 177 dotatate); Advanced Accelerator Applications; For the treatment of gastroenteropancreatic neuroendocrine tumors, Approved January 2018

Pulmonary/Respiratory Diseases

Symdeko (tezacaftor/ivacaftor) ; Vertex; For the treatment of cystic fibrosis , Approved February 2018

Urology

Erleada (apalutamide); Janssen Oncology; For the treatment of prostate cancer, Approved February 2018

Cardiology/Vascular Diseases

Bevyxxa (betrixaban); Portola Pharmaceuticals; For the the prophylaxis of venous thromboembolism, Approved June 2017

Dermatology

Bavencio (avelumab) ; EMD Serono/Pfizer; For the treatment of Merkel cell carcinoma , Approved March 2017
Baxdela (delafloxacin) tablets and injection; Melinta Therapeutics; For the treatment of acute bacterial skin and skin structure infections, Approved June 2017
Dupixent (dupilumab); Regeneron Pharmaceuticals; For the treatment of atopic dermatitis, Approved March 2017
Eskata (hydrogen peroxide); Aclaris Therapeutics; For the treatment of seborrheic keratoses, Approved December 2017
Rhofade (oxymetazoline hydrochloride); Allergan; For the treatment of facial erythema associated with rosacea, Approved January 2017
Siliq (brodalumab); Valeant Pharmaceuticals; For the treatment of plaque psoriasis , Approved February 2017
Tremfya (guselkumab); Janssen Biotech; For the treatment of moderate-to-severe plaque psoriasis, Approved July 2017
Xepi (ozenoxacin) ; Medimetriks; For the treatment of impetigo, Approved December 2017

Endocrinology

Macrilen (macimorelin); Stonebridge Biopharma; For the diagnosis of adult growth hormone deficiency , Approved December 2017
Ozempic (semaglutide); Novo Nordisk; For the treatment of type II diabetes, Approved December 2017
Parsabiv (etelcalcetide); Amgen; For the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis, Approved February 2017
Qtern (dapagliflozin and saxagliptin) ; AstraZeneca; For the treatment of inadequately controlled type II diabetes , Approved February 2017
Steglatro (ertugliflozin); Merck; For the treatment of type 2 diabetes mellitus, Approved December 2017

Family Medicine

Ozempic (semaglutide); Novo Nordisk; For the treatment of type II diabetes, Approved December 2017
Qtern (dapagliflozin and saxagliptin) ; AstraZeneca; For the treatment of inadequately controlled type II diabetes , Approved February 2017
Steglatro (ertugliflozin); Merck; For the treatment of type 2 diabetes mellitus, Approved December 2017
Trulance (plecanatide); Synergy Pharmaceuticals; For the treatment of adults with chronic idiopathic constipation, Approved January 2017

Gastroenterology

Symproic (naldemedine); Shionogi; For the treatment of opioid-induced constipation, Approved March 2017
Trulance (plecanatide); Synergy Pharmaceuticals; For the treatment of adults with chronic idiopathic constipation, Approved January 2017
Xermelo (telotristat ethyl); Lexicon Pharmaceuticals; For the treatment of carcinoid syndrome diarrhea, Approved February 2017

Genetic Disease

Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) ; CSL Behring; For the routine prophylaxis to prevent Hereditary Angioedema attacks, Approved June 2017
Brineura (cerliponase alfa); BioMarin; For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Approved April 2017
Mepsevii (vestronidase alfa-vjbk) ; Ultragenyx; For the treatment of Mucopolysaccharidosis VII , Approved November 2017

Hematology

Aliqopa (copanlisib); Bayer; For the treatment of follicular lymphoma , Approved September 2017
Besponsa (inotuzumab ozogamicin); Pfizer; For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, Approved August 2017
Calquence (acalabrutinib); Acerta Pharmaceuticals; For the treatment of mantle cell lymphoma , Approved November 2017
Endari (L-glutamine oral powder); Emmaus Life Sciences; For the treatment of sickle cell disease , Approved July 2017
Giapreza (angiotensin II) ; La Jolla Pharmaceuticals; For the treatment of septic shock, Approved December 2017
Hemlibra (emicizumab-kxwh); Genentech; For the prevention or reduction of bleeding episodes in patients with hemophilia A , Approved November 2017
IDHIFA (enasidenib); Celgene; For the treatment of relapsed or refractory acute myeloid leukemia with IDH2 mutation , Approved August 2017
Kymriah (tisagenlecleucel); Novartis; For the treatment of refractory B-cell precursor acute lymphoblastic leukemia , Approved August 2017
Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) ; Novo Nordisk; For the treatment of hemophilia B, Approved June 2017
Rydapt (midostaurin); Novartis; For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis , Approved April 2017
Vyxeos (daunorubicin and cytarabine) ; Jazz Pharma; For the treatment of newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes, Approved August 2017
Yescarta (axicabtagene ciloleucel); Kite Pharmaceuticals; For the treatment of relapsed or refractory large B-cell lymphomas, Approved October 2017
Hepatology (Liver, Pancreatic, Gall Bladder)
Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] ; Dynavax; For the prevention of hepatitis B virus infection, Approved November 2017
Mavyret (glecaprevir and pibrentasvir) ; AbbVie; For the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6, Approved August 2017
Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) ; Gilead; For the treatment of hepatitis C, Approved July 2017

Immunology

Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) ; CSL Behring; For the routine prophylaxis to prevent Hereditary Angioedema attacks, Approved June 2017
Actemra (tocilizumab) injection; Genentech; For the treatment of CAR T cell-induced severe or life-threatening cytokine release syndrome, Approved September 2017
Ocrevus (ocrelizumab); Genentech; For the treatment of multiple sclerosis, Approved March 2017
Tremfya (guselkumab); Janssen Biotech; For the treatment of moderate-to-severe plaque psoriasis, Approved July 2017
Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) ; Gilead; For the treatment of hepatitis C, Approved July 2017
Zerviate (cetirizine ophthalmic solution 0.24%); NicOx; For the treatment of ocular itching associated with allergic conjunctivitis, Approved May 2017

Infections and Infectious Diseases

Baxdela (delafloxacin) tablets and injection; Melinta Therapeutics; For the treatment of acute bacterial skin and skin structure infections, Approved June 2017
Benznidazole; Chemo Group; For the treatment of Chagas disease , Approved August 2017
Giapreza (angiotensin II) ; La Jolla Pharmaceuticals; For the treatment of septic shock, Approved December 2017
Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] ; Dynavax; For the prevention of hepatitis B virus infection, Approved November 2017
Juluca (dolutegravir and rilpivirine); ViiV Healthcare; For the treatment of HIV-1 infection in adults, Approved November 2017
KedRab [Rabies Immune Globulin (Human)]; Kedrion Biopharma ; For the post-exposure prophylaxis of rabies infection, Approved August 2017
Mavyret (glecaprevir and pibrentasvir) ; AbbVie; For the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6, Approved August 2017
Prevymis (letermovir) ; Merck; For the prevention of cytomegalovirus following allogenic hematopoietic stem cell transplant, Approved November 2017
Shingrix (Zoster Vaccine Recombinant, Adjuvanted) ; GlaxoSmithKline; For the prevention of herpes zoster (shingles), Approved October 2017
Solosec (secnidazole) ; Symbiomix Therapeutics; For the treatment of bacterial vaginosis , Approved September 2017
Vabomere (meropenem and vaborbactam); The Medicines Company; For the treatment of complicated urinary tract infections , Approved August 2017
Xepi (ozenoxacin) ; Medimetriks; For the treatment of impetigo, Approved December 2017

Internal Medicine

Duzallo (lesinurad and allopurinol) ; Ardea Biosciences; For the treatment of hyperuricemia associated with gout , Approved August 2017

Musculoskeletal

Brineura (cerliponase alfa); BioMarin; For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Approved April 2017
Duzallo (lesinurad and allopurinol) ; Ardea Biosciences; For the treatment of hyperuricemia associated with gout , Approved August 2017
Emflaza (deflazacort); Marathon Pharmaceuticals; For the treatment of Duchenne muscular dystrophy, Approved February 2017
Kevzara (sarilumab); Sanofi ; For the treatment of active rheumatoid arthritis, Approved May 2017
Ocrevus (ocrelizumab); Genentech; For the treatment of multiple sclerosis, Approved March 2017
Tymlos (abaloparatide) ; Radius Health; For the treatment of postmenopausal women with osteoporosis at high risk for fracture, Approved April 2017
Zilretta (triamcinolone acetonide extended-release injectable suspension); Flexion Therapeutics; For the treatment of osteoarthritis knee pain, Approved October 2017

Nephrology

Parsabiv (etelcalcetide); Amgen; For the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis, Approved February 2017

Neurology

Austedo (deutetrabenazine) ; Teva Pharmaceuticals; For the treatment of chorea associated with Huntington’s disease and tardive dyskinesia , Initial approval April 2017
Brineura (cerliponase alfa); BioMarin; For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Approved April 2017
Gocovri (amantadine) ; Adamas Pharmaceuticals; For the treatment of Parkinson's disease dyskinesia, Approved August 2017
Ingrezza (valbenazine); Neurocrine Biosciences; For the treatment of tardive dyskinesia, Approved April 2017
Radicava (edaravone); Mitsubishi Tanabe Pharma; For the treatment of amyotrophic lateral sclerosis , Approved May 2017
Xadago (safinamide); Newron Pharmaceuticals; For the treatment of Parkinson's disease, Approved March 2017

Obstetrics/Gynecology (Women’s Health)

Kisqali (ribociclib); Novartis; For the treatment of breast cancer, Approved March 2017
Solosec (secnidazole) ; Symbiomix Therapeutics; For the treatment of bacterial vaginosis , Approved September 2017
Tymlos (abaloparatide) ; Radius Health; For the treatment of postmenopausal women with osteoporosis at high risk for fracture, Approved April 2017
Verzenio (abemaciclib); Eli Lilly; For the treatment of HR+, HER2- breast cancer, Approved September 2017
Zejula (niraparib); Tesaro; For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer , Approved March 2017

Oncology

Aliqopa (copanlisib); Bayer; For the treatment of follicular lymphoma , Approved September 2017
Alunbrig (brigatinib); Ariad Pharmaceuticals; For the treatment of advanced ALK-positive metastatic non-small cell lung cancer, Approved April 2017
Bavencio (avelumab) ; EMD Serono/Pfizer; For the treatment of Merkel cell carcinoma , Approved March 2017
Besponsa (inotuzumab ozogamicin); Pfizer; For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, Approved August 2017
Calquence (acalabrutinib); Acerta Pharmaceuticals; For the treatment of mantle cell lymphoma , Approved November 2017
IDHIFA (enasidenib); Celgene; For the treatment of relapsed or refractory acute myeloid leukemia with IDH2 mutation , Approved August 2017
Imfinzi (durvalumab); AstraZeneca; For the treatment of advanced or metastatic urothelial carcinoma and Stage III non-small cell lung cancer, Initially approved May 2017
Kisqali (ribociclib); Novartis; For the treatment of breast cancer, Approved March 2017
Kymriah (tisagenlecleucel); Novartis; For the treatment of refractory B-cell precursor acute lymphoblastic leukemia , Approved August 2017
Nerlynx (neratinib); Puma Biotech; For the treatment of HER2 breast cancer, Approved July 2017
Rydapt (midostaurin); Novartis; For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis , Approved April 2017
Verzenio (abemaciclib); Eli Lilly; For the treatment of HR+, HER2- breast cancer, Approved September 2017
Vyxeos (daunorubicin and cytarabine) ; Jazz Pharma; For the treatment of newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes, Approved August 2017
Xermelo (telotristat ethyl); Lexicon Pharmaceuticals; For the treatment of carcinoid syndrome diarrhea, Approved February 2017
Yescarta (axicabtagene ciloleucel); Kite Pharmaceuticals; For the treatment of relapsed or refractory large B-cell lymphomas, Approved October 2017
Zejula (niraparib); Tesaro; For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer , Approved March 2017

Ophthalmology

Luxturna (voretigene neparvovec); Spark Therapeutics; For the treatment of vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease, Approved December 2017
Rhopressa (netarsudil ophthalmic solution) ; Aerie Pharmaceuticals; For the treatment of glaucoma or ocular hypertension, Approved December 2017
Vyzulta (latanoprostene bunod ophthalmic solution); Bausch & Lomb; For the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved November 2017
Zerviate (cetirizine ophthalmic solution 0.24%); NicOx; For the treatment of ocular itching associated with allergic conjunctivitis, Approved May 2017

Pediatrics/Neonatology

Brineura (cerliponase alfa); BioMarin; For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Approved April 2017
Emflaza (deflazacort); Marathon Pharmaceuticals; For the treatment of Duchenne muscular dystrophy, Approved February 2017
Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) ; Novo Nordisk; For the treatment of hemophilia B, Approved June 2017

Pharmacology/Toxicology

Actemra (tocilizumab) injection; Genentech; For the treatment of CAR T cell-induced severe or life-threatening cytokine release syndrome, Approved September 2017
Gocovri (amantadine) ; Adamas Pharmaceuticals; For the treatment of Parkinson's disease dyskinesia, Approved August 2017

Pulmonary/Respiratory Diseases

Imfinzi (durvalumab); AstraZeneca; For the treatment of advanced or metastatic urothelial carcinoma and Stage III non-small cell lung cancer, Initially approved May 2017

Rheumatology

Duzallo (lesinurad and allopurinol) ; Ardea Biosciences; For the treatment of hyperuricemia associated with gout , Approved August 2017
Kevzara (sarilumab); Sanofi ; For the treatment of active rheumatoid arthritis, Approved May 2017
Zilretta (triamcinolone acetonide extended-release injectable suspension); Flexion Therapeutics; For the treatment of osteoarthritis knee pain, Approved October 2017

Urology

Imfinzi (durvalumab); AstraZeneca; For the treatment of advanced or metastatic urothelial carcinoma and Stage III non-small cell lung cancer, Initially approved May 2017
Vabomere (meropenem and vaborbactam); The Medicines Company; For the treatment of complicated urinary tract infections , Approved August 2017

Vaccines

Shingrix (Zoster Vaccine Recombinant, Adjuvanted) ; GlaxoSmithKline; For the prevention of herpes zoster (shingles), Approved October 2017

Cardiology/Vascular Diseases

Byvalson (nebivolol and valsartan); Allergan; For the treatment of hypertension, Approved June 2016
Yosprala (aspirin and omeprazole); Aralez Pharmaceuticals; For the prevention of cardiovascular and cerebrovascular events, Approved September 2016

Dermatology

Ameluz (aminolevulinic acid hydrochloride); Biofrontera Pharma; For the treatment of actinic keratoses, Approved May 2016
Eucrisa (crisaborole) ointment; Pfizer; For the treatment of atopic dermatitis, Approved December 2016
Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis and active psoriatic arthritis, Approved March 2016

Endocrinology

Adlyxin (lixisenatide); Sanofi Aventis; For the treatment of type II diabetes, Approved July 2016
Soliqua 100/33 (insulin glargine and lixisenatide injection); Sanofi Aventis; For the treatment of inadequately controlled type II diabetes, Approved November 2016
Xultophy 100/3.6 (insulin degludec and liraglutide injection); Novo Nordisk; For the treatment of inadequately controlled type II diabetes, Approved November 2016

Family Medicine

Byvalson (nebivolol and valsartan); Allergan; For the treatment of hypertension, Approved June 2016
Onzetra Xsail (sumatriptan nasal powder) ; Avanir; For the treatment of migraine, Approved January 2016
Soliqua 100/33 (insulin glargine and lixisenatide injection); Sanofi Aventis; For the treatment of inadequately controlled type II diabetes, Approved November 2016
Xultophy 100/3.6 (insulin degludec and liraglutide injection); Novo Nordisk; For the treatment of inadequately controlled type II diabetes, Approved November 2016

Gastroenterology

Zinplava (bezlotoxumab); Merck; For the treatment of recurrent Clostridium difficile infection in patients receiving antibacterial treatment, Approved October 2016

Genetic Disease

Spinraza (nusinersen); Biogen; For the treatment of spinal muscular atrophy, Approved December 2016

Hematology

Afstyla (Antihemophilic Factor (Recombinant), Single Chain); CSL Behring; For the treatment of hemophillia A, Approved May 2016
Idelvion (Coagulation Factor IX (Recombinant), Albumin Fusion Protein); CSL Behring; For the treatment of hemophilia B, Approved March 2016
Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ; For the treatment of hemophillia A, Approved March 2016
Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of classical Hodgkin lymphoma, Approved May 2016
Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016

Hepatology (Liver, Pancreatic, Gall Bladder)

Defitelio (defibrotide sodium); Jazz Pharmaceuticals; For the treatment of hepatic veno-occlusive disease with renal or pulmonary dysfunction following HSCT, Approved March 2016
Ocaliva (obeticholic acid); Intercept Pharmaceuticals; For the treatment of primary biliary cholangitis, Approved May 2016
Vemlidy (tenofovir alafenamide); Gilead Sciences; For the treatment of chronic hepatitis B , Approved November 2016
Zepatier (elbasvir and grazoprevir); Merck; For the treatment of chronic HCV genotypes 1 or 4 , Approved January 2016

Immunology

Afstyla (Antihemophilic Factor (Recombinant), Single Chain); CSL Behring; For the treatment of hemophillia A, Approved May 2016
Descovy (emtricitabine and tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection, Approved April 2016
Epclusa (sofosbuvir and velpatasvir) ; Gilead Sciences; For the treatment of hepatitis C, Approved June 2016
Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 as initial therapy, Approved March 2016
Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis and active psoriatic arthritis, Approved March 2016
Vaxchora (Cholera Vaccine, Live, Oral); PaxVax; For active immunization against Cholera, Approved June 2016

Infections and Infectious Diseases

Anthim (obiltoxaximab); Elusys Therapeutics; For the treatment of inhalational anthrax , Approved March 2016
Descovy (emtricitabine and tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection, Approved April 2016
Epclusa (sofosbuvir and velpatasvir) ; Gilead Sciences; For the treatment of hepatitis C, Approved June 2016
Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 as initial therapy, Approved March 2016
Syndros (dronabinol oral solution); Insys Therapeutics; For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy, Approved July 2016
Vaxchora (Cholera Vaccine, Live, Oral); PaxVax; For active immunization against Cholera, Approved June 2016
Vemlidy (tenofovir alafenamide); Gilead Sciences; For the treatment of chronic hepatitis B , Approved November 2016
Zepatier (elbasvir and grazoprevir); Merck; For the treatment of chronic HCV genotypes 1 or 4 , Approved January 2016
Zinplava (bezlotoxumab); Merck; For the treatment of recurrent Clostridium difficile infection in patients receiving antibacterial treatment, Approved October 2016

Musculoskeletal

Exondys 51 (eteplirsen); Sarepta Therapeutics; For the treatment of Duchenne muscular dystrophy with mutated DMD gene amenable to exon 51 skipping, Approved September 2016
Spinraza (nusinersen); Biogen; For the treatment of spinal muscular atrophy, Approved December 2016
Zinbryta (daclizumab) ; Biogen; For the treatment of relapsing multiple sclerosis, Approved May 2016

Nephrology

Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016
Lenvima (lenvatinib); Eisai; For the treatment of advanced renal cell carcinoma, Approved May 2016
Rayaldee (calcifediol) ; Opko Health; For the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, Approved June 2016

Neurology

Briviact (brivaracetam); UCB; For the treatment of partial onset seizures related to epilepsy, Approved February 2016
Carnexiv (carbamazepine); Lundbeck; replacement therapy when oral administration is not feasible, in adults with seizures, Approved October 2016
Exondys 51 (eteplirsen); Sarepta Therapeutics; For the treatment of Duchenne muscular dystrophy with mutated DMD gene amenable to exon 51 skipping, Approved September 2016
Nuplazid (pimavanserin); Acadia Pharmaceuticals; For the treatment of hallucinations and delusions associated with Parkinson’s disease, Approved April 2016
Nuplazid (pimavanserin); Acadia Pharmaceuticals; For the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, Approved May 2016
Onzetra Xsail (sumatriptan nasal powder) ; Avanir; For the treatment of migraine, Approved January 2016
Spinraza (nusinersen); Biogen; For the treatment of spinal muscular atrophy, Approved December 2016
Troxyca ER (oxycodone + naltrexone); Pfizer; For the management of severe pain, Approved August 2016
Zinbryta (daclizumab) ; Biogen; For the treatment of relapsing multiple sclerosis, Approved May 2016

Obstetrics/Gynecology (Women’s Health)

Intrarosa (prasterone vaginal insert); Endoceutics; For the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause, Approved November 2016
Rubraca (rucaparib); Clovis Oncology; For the treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutation, Approved December 2016

Oncology

Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016
Keytruda (pembrolizumab); Merck; For the treatment of head and neck squamous cell cancer , Approved August 2016
Lartruvo (olaratumab) ; Eli Lilly; For the treatment of soft tissue sarcoma, Approved October 2016
Lenvima (lenvatinib); Eisai; For the treatment of advanced renal cell carcinoma, Approved May 2016
Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of classical Hodgkin lymphoma, Approved May 2016
Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck, Approved November 2016
Rubraca (rucaparib); Clovis Oncology; For the treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutation, Approved December 2016
Sustol (granisetron); Heron Therapeutics; For the prevention of chemotherapy-induced nausea and vomiting, Approved August 2016
Syndros (dronabinol oral solution); Insys Therapeutics; For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy, Approved July 2016
Tecentriq (atezolizumab); Genentech; For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer, Approved May 2016
Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016

Ophthalmology

Humira (adalimumab); Abbvie; For the treatment of uveitis, Approved July 2016
Xiidra (lifitegrast); Shire; For the treatment of dry eye disease, Approved July 2016

Pediatrics/Neonatology

Exondys 51 (eteplirsen); Sarepta Therapeutics; For the treatment of Duchenne muscular dystrophy with mutated DMD gene amenable to exon 51 skipping, Approved September 2016
Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ; For the treatment of hemophillia A, Approved March 2016
Spinraza (nusinersen); Biogen; For the treatment of spinal muscular atrophy, Approved December 2016

Pharmacology/Toxicology

Sustol (granisetron); Heron Therapeutics; For the prevention of chemotherapy-induced nausea and vomiting, Approved August 2016

Psychiatry/Psychology

Nuplazid (pimavanserin); Acadia Pharmaceuticals; For the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, Approved May 2016

Pulmonary/Respiratory Diseases

Bevespi Aerosphere (glycopyrrolate and formoterol fumarate); AstraZeneca; For the treatment of chronic obstructive pulmonary disease, Approved April 2016
Cinqair (reslizumab); Teva Pharmaceuticals; For the treatment of severe asthma, Approved March 2016
Tecentriq (atezolizumab); Genentech; For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer, Approved May 2016

Rheumatology

Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis and active psoriatic arthritis, Approved March 2016

Urology

Tecentriq (atezolizumab); Genentech; For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer, Approved May 2016

Vaccines

Vaxchora (Cholera Vaccine, Live, Oral); PaxVax; For active immunization against Cholera, Approved June 2016